Trump aides contact Google, Meta, Snap over online drug sales, The Information reports

Published 12/08/2024, 02:32 PM
Updated 12/09/2024, 12:36 PM
© Reuters. FILE PHOTO: A 3D printed Facebook's new rebrand logo Meta is seen in front of displayed Google logo in this illustration taken on November 2, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
MSFT
-
GOOGL
-
META
-

(Reuters) -President-elect Donald Trump's transition team has invited five major tech companies, including Google (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT) and Meta Platforms (NASDAQ:META) to a meeting in mid-December about dealing with online sales of drugs, The Information reported on Sunday.

A representative for Jim Carroll, the drug czar during Trump's first term, and Trump's transition team emailed staffers from the three tech giants on Thursday, as well as those from Snap and TikTok, to invite them to a call, the report added, citing a person with direct knowledge of the correspondence.

The transition officials want to hear from the companies about their priorities and any barriers to addressing issues around the sales of drugs online, the person told the Information.

Google, Microsoft, Meta, Snap, TikTok and the Trump transition team did not immediately respond to a Reuters' request for comment.

Trump has vowed to get Mexico to do more to stop the flow of fentanyl to the U.S., which has killed hundreds of thousands of Americans and threatened to impose steep tariffs on goods from Mexico and Canada unless those countries curb fentanyl trafficking and illegal migration.

In November, Trump also said in a post on Truth Social that he "will be working on a large scale United States Advertising Campaign, explaining how bad fentanyl is for people to use."

© Reuters. REUTERS/Dado Ruvic

In March, The Wall Street Journal reported that U.S. prosecutors were investigating Meta's role and whether it profited from the sale and distribution of drugs on Facebook and Instagram.

In January, eBay (NASDAQ:EBAY) agreed to pay $59 million and upgrade compliance measures to resolve U.S. Department of Justice allegations that it didn't do enough to stop criminals from buying devices for making counterfeit drugs, including pills laced with fentanyl.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.